UPPSALA, Sweden – Q-linea continues to advance its molecular diagnostics program, with the aim of making pathogen identification and antibiotic susceptibility tests available for clinical use by the end of 2015.

At the same time, the Swedish company is encouraged by the use of its technology in an EU-funded biothreat detection project, and it may continue to develop its platform for security-related applications, according to CEO Jonas Jarvius.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.